Back to top
more

ProNAi Therapeutics, Inc. (DNAI)

(Delayed Data from NSDQ)

$1.56 USD

1.56
428,167

-0.07 (-4.29%)

Updated Jan 9, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

[DNAI]

Reports for Purchase

Showing records 1 - 14 ( 14 total )

Industry: Medical - Biomedical and Genetics

Record: 1

06/06/2016

Company Report

Pages: 6

Downgrading to NEUTRAL and Lowering PT to $3; PNT2258 Development Suspended Due to Low Response Rates in Wolverine

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

05/27/2016

Daily Note

Pages: 4

DNAI Expands Pipeline with Licensing of Cdc7 Inhibitor AS-141, Reiterate OUTPERFORM and $36 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

05/19/2016

Industry Report

Pages: 8

ASCO 2016 Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

05/11/2016

Company Report

Pages: 7

Q1 EPS; Interim Wolverine Data Ahead at ASCO, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

04/08/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 11

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

03/04/2016

Company Report

Pages: 8

Q4:15 EPS; Wolverine Data in DLBCL on Track for ASCO,Richter''s Data YE:16, Reiterate OUTPERFORM and $36 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

01/29/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

01/14/2016

Industry Report

Pages: 6

After a Rough Start, Opportunities Begin to Stand Out

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

12/17/2015

Industry Report

Pages: 10

Biotech Year-End Review, What to Expect in 2016

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

11/05/2015

Company Report

Pages: 6

Q3:15 Results; Looking Ahead to Data and Further Ph 2 Initiations in 2016, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

11/05/2015

Company Report

Pages: 5

Q3:15 Results; Looking Ahead to Data and Further Ph 2 Initiations in 2016, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

10/30/2015

Daily Note

Pages: 4

DNAI Initiates Study of PNT2258 in Richter''s patients, Setting up Busy 2016. Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

08/21/2015

Company Report

Pages: 5

Q2:EPS; Preparing to Initiate Registration-Focused Richter''s Transformed CLL Trial, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

08/10/2015

Company Report

Pages: 25

Initiating with OUTPERFORM and $36 Price Target; DNAi - Turning off Oncogenes at the Source

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party
// eof